<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909621</url>
  </required_header>
  <id_info>
    <org_study_id>COPRA</org_study_id>
    <nct_id>NCT02909621</nct_id>
  </id_info>
  <brief_title>Evaluation of FLEXOFYTOL® Versus PLACEBO</brief_title>
  <acronym>COPRA</acronym>
  <official_title>Evaluation of Efficacy, Tolerance, and Dose Effects of a Curcuma Extract (FLEXOFYTOL®) Versus PLACEBO in Patients With Knee osteoARthritis (COPRA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tilman S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Artialis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tilman S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, double-blind, placebo-controlled with 3
      parallel-groups and multicenter trial in patients suffering from knee OA (osteoarthrosis).

      A first exploratory non comparative study (TILFLEXY002, NCT01909037, Henrotin et al., 2014
      BMC Complementary and Alternative Medicine) evaluated the efficacy of FLEXOFYTOL® at the dose
      of 2x3 caps/day, during a 3-month period, in 22 patients suffering from knee OA, on the serum
      levels of cartilage-specific and inflammatory biomarkers, on the evaluation of pain and on
      the global patient assessment of disease activity.

      This study demonstrated a statistically significant decrease of sColl2-1 cartilage specific
      biomarker, an early decrease of the ultrasensitive C-reactive protein (CRP), an improvement
      of the global assessment of the disease by the patient as well as a good tolerance and
      compliance for the treatment. Results of this exploratory study are encouraging and justify
      the setup of a randomized, placebo-controlled double blind and dose-ranging trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      150 patients suffering from symptomatic knee OA will be randomized in 3 parallel groups (50
      patients per group). Each patient will be enrolled in the study for 6 months including 4
      visits: Inclusion visit (T0), follow-up visits after 1 month (T1), 3 months (T3) and 6 months
      (T6).

      A. Primary objective

      - Evaluate the efficacy of two different dosages of FLEXOFYTOL® versus PLACEBO on arthritis
      related biomarker coll2-1 and on patient assessment of disease activity in patients suffering
      from knee OA after a 3 months treatment

      B. Secondary objectives

        -  Evaluate the efficacy of two different dosages of FLEXOFYTOL® versus PLACEBO on
           arthritis-related and inflammatory biomarkers.

        -  Evaluate the efficacy of two different dosages of FL EXOFYTOL® versus PLACEBO on pain
           and function.

        -  Evaluate the tolerance, the compliance and the patients' satisfaction.

        -  Evaluate the use of rescue treatments i.e. Paracetamol and oral non-steroidal
           antiinflammatory drugs (NSAIDs) during the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of serum levels of sColl2-1 biomarker between T0 and T3 by specific immunoassays (Enzyme-linked Immunosorbent assay, ELISA).</measure>
    <time_frame>3 months (between T0 and T3 visit)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of Global assessment of disease activity by the patient using a Visual analogue scale (VAS) between T0 and T3.</measure>
    <time_frame>3 months (between T0 and T3 visit)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of serum levels of sColl2-1 (type II collagen degradation) and ultrasensitive CRP (C-reactive protein) biomarkers by specific immunoassays (Enzyme-linked Immunosorbent assay, ELISA).</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean knee pain over the last 24 hours using a visual analogue scale (VAS).</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of disease activity using a visual analogue scale (VAS).</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Incidence of Emergent Adverse Events (AE), drop-outs and safety issues using blood safety analyses on patients with AE (Tolerance).</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count the capsules in investigation kits brought back by the patient.</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage by UHPLC-MS/MS and monitoring of curcumin blood level to assess patient compliance.</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Patient's satisfaction by Likert scale.</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the use of rescue treatments i.e. Paracetamol and oral non-steroidal anti-inflammatory drugs (NSAIDs) during the study.</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome 8: Knee injury Osteoarthritis Outcome Score (KOOS) index and its subscale scores using a self-administered questionnaire.</measure>
    <time_frame>6 months (between T0 and T6 visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: FLEXOFYTOL® high dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: FLEXOFYTOL® low dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group C: PLACEBO</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FLEXOFYTOL®</intervention_name>
    <description>The product FLEXOFYTOL® is bio-optimized curcumin.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>curcuma extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the age of 45 and 80

        Exclusion Criteria:

          -  Artialis (study coordinator) or Tilman (Sponsor) 's employees

          -  Participation to a therapeutic clinical trial in the last 3 months

          -  Under guardianship or judicial protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Liège (CHU-Liège)-Coordinating Center</name>
      <address>
        <city>Liège</city>
        <state>Province Of Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032499/</url>
    <description>Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OsteoArthritis; FLEXOFYTOL®; Curcuma; biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Turmeric extract</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

